zoledronic acid
AssetSmall moleculeAlso AXS-02, oral zoledronate, Reclast, ZOL446
Inhibits farnesyl pyrophosphate synthase, preventing protein prenylation and osteoclast-mediated bone resorption.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Apoptosis
- Indications
- 53
- Trials
- 246
- Developers
- 2
Indications
53Bone metastases
Approvedaccessdata.fda.gov7 Oct 2026
Cancer
Approvedema.europa.eu7 Oct 2026
Fractures, Bone
Approvedema.europa.eu7 Oct 2026
50 more
- Targets and what it contains3
- Owner and partners2
- Trials246
- Evidence for its targets3
- Competitors12
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 60 sources